Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6343
Gene Symbol: SCT
SCT
0.040 GeneticVariation disease BEFREE Although allo-SCT remains an important treatment option for patients with T315I-positive advanced CML and Ph+ ALL, ponatinib represents a valuable alternative for patients with T315I-positive CP-CML.Cancer 2017;123:2875-80.© 2017 American Cancer Society. 28387926 2017
Entrez Id: 6343
Gene Symbol: SCT
SCT
0.040 Biomarker disease BEFREE In conclusion, administration of nilotinib post allo-SCT, in attempt to reduce relapse rates or progression of Ph+ ALL and CML, did not jeopardize immune reconstitution or function following transplantation. 27880933 2017
Entrez Id: 6343
Gene Symbol: SCT
SCT
0.040 Biomarker disease BEFREE We analyzed the clinical outcome of therapy using dasatinib, a second-generation TKI, in 9 patients with relapsed Ph(+)ALL after allo-SCT. 25445469 2015
Entrez Id: 6343
Gene Symbol: SCT
SCT
0.040 Biomarker disease BEFREE Because of a lack of adverse effects of imatinib on transplantation outcome, a treatment strategy consisting of molecular monitoring-guided initiation of imatinib followed by RI-UCBT may be promising in the management of Ph+ ALL after allogeneic SCT. 16926141 2006